Climb Bio (CLYM) is trading down at $9.19 (-0.97%) on NASDAQ, as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Current price targets from 2 firms average $26, ranging from $25 to $27 — 183% above the current $9.19. Each is tracked to its date and scored the same way a member's call is.
2 targets, newest first. Open a row for its source and scoring.
Entry price $10.1, the close nearest Nov 6, 2026, when the target was reported; the target is +168% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.
Scoring Open: judged on the close on Nov 6, 2027.
Wedbush raised its price target to $27 from $25
Entry price $10.3, the close nearest Nov 6, 2026, when the target was reported; the target is +143% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.
Scoring Open: judged on the close on Nov 6, 2027.
Oppenheimer reiterated an Outperform rating and $25.00 price target on Climb Bio (NASDAQ:CLYM) shares.
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$20.9M | −$35.7M | −$45.1M | −$40.3M | −$82.0M | −$67.9M |
| Net income | −$20.7M | −$47.5M | −$45.2M | −$35.1M | −$73.9M | −$59.9M |
| EPS (diluted) | −$4.66 | −$2.83 | −$1.72 | −$1.30 | −$1.53 | −$0.88 |
| Balance sheet | ||||||
| Cash and equivalents | $20.5M | $46.9M | $43.6M | $93.1M | $87.2M | $35.7M |
| Total assets | $24.6M | $173.2M | $135.0M | $110.5M | $217.2M | $167.7M |
| Total liabilities | $3.06M | $6.04M | $6.28M | $2.87M | $5.31M | $7.27M |
| Shareholders' equity | −$25.0M | $167.2M | $128.7M | $107.6M | $211.9M | $160.5M |
| Cash flow | ||||||
| Operating cash flow | −$14.1M | −$36.1M | −$37.4M | −$20.6M | −$15.6M | −$54.4M |
| Capital expenditure | — | — | — | $0 | $0 | $186.0K |
| Free cash flow | — | — | — | −$20.6M | −$15.6M | −$54.5M |
| Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | Q3 FY26Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$10.9M | −$23.0M | −$10.7M | −$14.9M | −$19.3M | −$15.2M | −$15.4M | −$16.9M |
| Net income | −$8.42M | −$20.8M | −$8.67M | −$12.9M | −$17.5M | −$13.7M | −$13.5M | −$14.6M |
| EPS (diluted) | $0.04 | −$0.31 | −$0.13 | −$0.19 | −$0.25 | −$0.20 | −$0.18 | −$0.18 |
| Balance sheet | ||||||||
| Cash and equivalents | $87.2M | $29.0M | $22.7M | $25.8M | $35.7M | $8.36M | $44.1M | $39.7M |
| Total assets | $217.2M | $200.7M | $192.4M | $182.3M | $167.7M | $152.4M | $246.3M | $236.6M |
| Total liabilities | $5.31M | $7.36M | $6.62M | $5.30M | $7.27M | $4.29M | $6.75M | $8.51M |
| Shareholders' equity | $211.9M | $193.4M | $185.8M | $177.0M | $160.5M | $148.1M | $239.5M | $228.1M |
| Cash flow | ||||||||
| Operating cash flow | −$5.52M | −$15.4M | −$11.1M | −$12.1M | −$15.6M | −$14.4M | −$10.5M | −$12.0M |
| Capital expenditure | $0 | — | — | $109.0K | $0 | — | — | $820.0K |
| Free cash flow | −$5.52M | — | — | −$12.2M | −$15.6M | — | — | −$12.8M |
From Climb Bio's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Read at Investing.com ↗ Link to this story
Read at Investing.com ↗ Link to this story
Read at Investing.com ↗ Link to this story
Also mentions Morgan Stanley